US President Joe Biden announced on the 22nd (local time) that pharmaceutical company Pfizer will supply 250,000 doses of Paxrovid, an oral treatment for COVID-19, in January next year.
In a statement published on the White House website in the name of President Biden, he said, “Today we have good news in the fight against COVID-19,” and announced the news of the FDA’s Emergency Use Authorization (EUA) for Paxrovid. “It is a promising treatment against omicron mutations that can significantly reduce hospitalizations and deaths.”
He evaluated the approval of Paxrovid as a significant step forward in escaping from the COVID-19 pandemic.
“We responded faster and more aggressively than any other country and secured 10 million servings,” he said.
“We recognize that it takes time to create a therapeutic given the complex scientific process, and production will increase in the coming months.”
In particular, he emphasized, “We will be able to use more than 250,000 doses of treatment in January (next year).” “We will work with state governments to ensure that they are distributed equitably to those areas and reach the communities most affected,” he added.
He also said that Pfizer is “working closely with them” to get a treatment done quickly. “We will provide all necessary resources,” he said, including the use of the Defense Materials Production Act (DPA).
“Despite the more contagious omicron mutation, the United States is more ready to fight this virus than ever. We have a vaccine, a booster shot, a test and now other effective treatments.” We will be able to further reduce the impact of COVID-19 on our country,” he said.
[서울=뉴시스]
